Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Allena Pharmaceuticals Inc (ALNA)

Allena Pharmaceuticals Inc (ALNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,103
  • Shares Outstanding, K 24,742
  • Annual Sales, $ 0 K
  • Annual Income, $ -47,340 K
  • 60-Month Beta 2.89
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.29
  • Number of Estimates 6
  • High Estimate -0.25
  • Low Estimate -0.33
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +46.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4713 +4.67%
on 06/29/20
3.3900 -54.57%
on 06/03/20
-1.1700 (-43.17%)
since 06/02/20
3-Month
0.9300 +65.59%
on 04/03/20
3.3900 -54.57%
on 06/03/20
+0.6701 (+77.03%)
since 04/02/20
52-Week
0.5250 +193.33%
on 03/16/20
6.3000 -75.56%
on 11/04/19
-3.3700 (-68.64%)
since 07/02/19

Most Recent Stories

More News
Allena Pharmaceuticals Announces $15.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and...

ALNA : 1.5400 (-3.14%)
Allena Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and...

ALNA : 1.5400 (-3.14%)
Allena Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

-- Revised URIROX-2 Trial Design to Potentially Reduce Size and Cost of Trial --

ALNA : 1.5400 (-3.14%)
Allena Pharmaceuticals, Inc. (ALNA) Moves to Strong Buy: Rationale Behind the Upgrade

Allena Pharmaceuticals, Inc. (ALNA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near...

ALNA : 1.5400 (-3.14%)
Allena Pharmaceuticals, Inc. (ALNA) Upgraded to Buy: Here's Why

Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ALNA : 1.5400 (-3.14%)
Allena Pharmaceuticals Reports Fourth Quarter 2019 and Full Year 2019 Financial Results and Provides Business Update

-- Streamlined URIROX-2 Design Potentially Reduces Target Length and Cost of Trial --

ALNA : 1.5400 (-3.14%)
Allena Pharmaceuticals to Present at 40th Annual Cowen & Co. Health Care Conference

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and...

ALNA : 1.5400 (-3.14%)
Allena Pharmaceuticals Announces Streamlined Design for URIROX-2, Second Pivotal Clinical Trial of Reloxaliase for Enteric Hyperoxaluria

-- Reducing Target Enrollment to 200 Subjects --

ALNA : 1.5400 (-3.14%)
Allena Pharmaceuticals, Inc. (ALNA) Upgraded to Buy: Here's Why

Allena Pharmaceuticals, Inc. (ALNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ALNA : 1.5400 (-3.14%)
Allena Pharmaceuticals Provides Updates on Reloxaliase Development Program and Corporate Activities

- Prioritizing Development of Reloxaliase for Patients with Enteric Hyperoxaluria (EH) -

ALNA : 1.5400 (-3.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ALNA with:

Business Summary

Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders primarily in the United States. The companys product candidate includes ALLN-177 and ALLN-346 which...

See More

Key Turning Points

2nd Resistance Point 1.6533
1st Resistance Point 1.5967
Last Price 1.5400
1st Support Level 1.4967
2nd Support Level 1.4533

See More

52-Week High 6.3000
Fibonacci 61.8% 4.0939
Fibonacci 50% 3.4125
Fibonacci 38.2% 2.7311
Last Price 1.5400
52-Week Low 0.5250

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar